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Transjugular Intrahepatic Portosystemic 
Shunt in the Treatment of Portal Hypertension 
F. Bartoli. A. Zajko. loR. Marino. P. Orons. C. Scotti-Foglieni. U. Cillo. A. Tzakis. J.J. Fung. T.E. Starzl 
The treatment of portal hypertension (PH) is an 
important problem in patients with end-stage liver 
disease (ESLO) who are candidates for orthotopic 
liver transplantation (OLTx). Variceal bleeding is a 
known major complication and the second leading 
cause of death after acute hepatic failure in portal 
hypertensive patients [1,2]. The management of var-
iceal bleeding in OLTx candidates should attempt to 
preserve the anatomy of the portal vein (PV). Previ-
ous reports have documented increased mortality 
and morbidity rates in patients with surgical porta-
caval shunts undergoing OLTx [3, 4]. 
In recent years, endoscopic sclerotherapy has be-
come the treatment of choice for acute variceal 
bleeding. Sclerotherapy is able to stop variceal 
bleeding in more than 90% of cases [5]. However, 
there is a high rate of reb lee ding episodes after scle-
rotherapy [6-9]. 
An emergency portosystemic shunt is indicated in 
those 10-15% of patients in whom sclerotherapy has 
failed to stop variceal bleeding. Other indications for 
an emergent portosystemic shunt are bleeding from 
large gastric or intestinal varices or hemorrhage from 
portal hypertensive gastropathy (PHG) [6-10]. 
The high rate of mortality and morbidity and the 
lack of a significant improvement in the long-term 
survival of patients with PH coupled with the evolu-
tion of OLTx have greatly reduced the indications for 
surgical portosystemic shunting [11-13]. Therefore, 
much effort has been directed at developing an ef-
fective nonsurgical technique of portal decompres-
sion. 
In 1969, Rosch et al. created a nonsurgical porto-
systemic shunt in dogs using a percutaneous trans-
jugular approach. This technique is based on the 
close relationship between the hepatic vein (HV) 
and a main branch of the PV. These authors used a 
modified Colapinto needle advanced through a vas-
cular catheter into a HV. The HY is punctured with 
the Colapinto needle which is then advanced 
through the hepatic tissue until the PY is cannulated. 
Finally, another catheter is inserted between the HY 
and the PY, thus creating an intrahepatic porta-caval 
shunt [14J. 
After this pioneering study, other investigators 
tried to create intrahepatic porta-caval shunts by re-
secting a cylinder of hepatic tissue [15] or using cl 
cryostatic probe [16) for making a tunnel through the 
hepatic parenchyma. 
In 1982, Colapinto et a1., using a technigue similar 
to that developed by Rosch, created a transjugular 
intrahepatic portosystemic shunt (TIPS) in a patient 
with massive variceal bleeding uncontrolled by bal-
loon tamponade and too sick for surgical operation 
[17]. These authors created a TIPS by using a vascu-
lar balloon dilatation catheter, which was left ex-
panded for 12 hours inside the hepatic tissue and 
then removed [17). Subseguently, the same authors 
reported on 6 Child's class C patients who under-
went a TIPS procedure according to the technigue 
described above [18]. In this study, only a slight re-
duction of portal pressure was obtained and all the 
shunts eventually occluded due to closure of the liv-
er tract. All patients died during a 6-month follow-
up for causes related to ESLD [18]. 
In 1985, and in a subsequent study in 1986, Palmaz 
et al. made a significant improvement in the long-
term patency of the intrahepatic shunt by using a 
new balloon expandable stainless steel vascular stent 
[19,20]. This metal stent was used to keep the artifi-
cially created tract in the liver open. The first clinical 
application of Palmaz's stent was reported by Richter 
in 1990 [21]. Further clinical studies confirmed the ef-
ficacy of this new technique of portal decompression 
encouraging its larger clinical application in the treat-




Medical therapv, sclerotherapv ilnd trclnshepatic 
embolization have illl been shown to be useful in the 
treatment of va ricea I hemorrhage. H ovvever, the cre-
ation of il portosvstemic s hunt is associated with the 
lowest incidence of rebleeding episodes [6-8, 23-26) . 
In this "vav, TIPS is th e result of il milrriage betweell 
the surgicill ilnd ilngiogrilphic experiencl' ill the 
treatment of PH , allowing for decompression the 
portal system without the risks rdilted to il surgical 
procedure. 
The most frequ e nt indiciltioll to perform TIPS is 
ilcute variceill bleeding that Cilnnot be s topped by 
sclerotherapy, in piltients \·vith poor generill medicill 
condition or ESLD thilt ilre ineligible for shunt sur-
gery. However, it is importilnt to stilbilize th e Pil-
tients clinicill condition before periormin g the TIPS . 
Most of such piltients ilre Child 's class B or C. It ha s 
been reported thilt emergency shunt operiltion s ill 
Child 's clilss C piltients cilrries il mortillitv as high ilS 
4EFD ~EF to 1O0 '}'; , [27-30J. 
Recently, it hilS been suggested thilt TIPS be per-
formed in patients llot ilctively bleeding but who 
have und ergon e repeated sessions of sclerotherilpy, 
or in patients thclt hilve experienced more thiln 2 
episodes of bleeding during 14 dilYs of observiltion 
[31 , 32] . 
Less frequent indications for TIPS procedure are 
recurrent ascites resistant to medicill therapy [33-40], 
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hepiltorenill svndrome or preoperilti\'e port ,ll dt'-
compression [33, 3-t) 
Poss ible contraindiciltions tor TIPS ilre hepiltic tu -
mor, lilrge hepiltic cyst or ilbscess, PV thrombosi s 
and/or venil CilVil thrombosis. An absolulL' contrilin-
diciltioll inr TIPS is polycystic liver diseilse. In the 
presence of PV thrombosis, it ma v still be poss ible to 
perform TIPS if c1 large intrahepatic portill collilterill 
is present (4 1). 
There is no reported experie nce o f TIPS in th e lit -
erature on pediatric patients, mos t likely because the 
smilll diameter of the vessels in children milke the 
procedure more difficult ilnd milV increa se the risk 
of thrombosis of the shunt. 
METHODS 
Before c1 TIPS procedure, prophylactic broild-spec-
trum ilntibiotics s hould be given ilnd severe cOilgulo-
path\" i i presen t, should be corrected . 
The firs t TIPS procedures were performed by u s-
in g il combined tran s jugulilr and percutaneou s trilll -
shepatic ilpproach , but this technique was quickly 
abandoned beciluse of the higher complication rate 
related to the transhepiltic cilnnulation of th e PV [21, 
42, 43] . 
As experience hilS been gained , most TIPS proce-
dures are compl e tely performed with o nly a trans-
Fig. 3.1. TransjuguJar intrahepatic portosystemic shunt using the WaJ/stent. 
A. Numerous gastroesophageal varices originating from the coronary vein are demonstrated on initial portogram following cath-
eter placement into the portal vein. The portosystemic gradient was 33 mmHg. 
B. Portogram performed following placement of Wallstent shows decompression of varices and excellent flow through the shunt 
into the inferior vena cava and right atrium. The portosystemic gradient was reduced to 14 mmHg. 
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jugular approach under fluoroscopy; doppler ultra-
sound mav be useful for PY localization [32,41, 43, 44]. 
A :; F slightlY curved catheter is coaxially guided 
through a 7 F ou ter teflon catheter and passed to the 
suprahepatic inferior vena cava (lye) via an internal 
jugular venous puncture site. The 5 F catheter is ad-
vanced into the right HY and a hepatic venogram is 
obtained. If the HY appears suitable for a TIPS, the 5 
F catheter is then removed and the 7 F teflon cathe-
ter is advanced into the HY; passage over a guide 
wire may be required to avoid kinking. A 16-G Ross 
modified Colapinto needle is then advanced through 
the 7 F teflon catheter into the HY. The HY puncture 
site is selected approximately 2 cm beyond the junc-
tion of the HY and lYe. Generally, the needle tip is 
rotated to an anterior direction. The needle is ad-
vanced through the hepatic parenchyma until a PY 
branch, usually the right, is entered. The PY access 
is confirmed by blood aspiration and visualization of 
the portal system by injection of water soluble con-
trast. Investigators have suggested that real time ul-
trasound can be useful in decreasing the number of 
attempts of PY puncture [32,43,44]. However, other 
investigators consider real time ultrasound guidance 
unhelpful, with fluoroscopy more than sufficient to 
achieve PY cannulation [41]. 
Once the PY is entered, a guide wire is advanced 
into the PY. The needle is then removed and a 5 F 
catheter is advanced into the PY over the guide wire. 
The venous pressure gradient between the PY and 
supra hepatic IYC or right atrium is measured and a 
portal venogram is performed to demonstrate the 
anatomy of the portal venous system (Fig. 3.1 A). The 
5 F catheter and the 7 F teflon catheter are exchanged 
for a 35 cm 9 or 10 F sheath which is passed to the HY. 
This exchange is performed over a heavy duty guide 
wire. A 10 mm balloon is then passed through the 
sheath into the liver tract. After balloon dilatation of 
the hepatic parenchymal tract, the balloon is re-
moved. Finally, an expandable metal stent is placed in 
the liver tract between the HY and the PY. Since a 
functional portosystemic shunt has been created, a 
vascular catheter is inserted into the portal system to 
demonstrate a decreased portosystemic gradient, the 
shunt flow and the status of varices (Fig. 3.1 B). If the 
reduction in portal pressure is not considered ade-
quate to achieve good portal decompression, it is pos-
sible to expand the intrahepatic shunt from 8 to 12 
mm in diameter, if a Palmaz stent has been used. 
The placement of a second shunt in a different posi-
tion can be an alternative technique to enlargement of 
the shunt previously described, if the intrahepatic 
shunt has been created with a Wallstent. Because ofits 
design, Wallstent cannot be enlarged beyond 10 mm. 
WORLDWIDE EXPERIENCE 
Until recentlv, onlv a limited number of TIPS cases 
has been reported in the international literature. 
As discussed above, Cola pinto et al. reported the 
results of 6 patients who underwent TIPS. These au-
thors demonstrated variceal obliteration and ob-
tained a portal pressure reduction of 10-15 mmHg, 
with a 70% rate of rebleeding episodes and 100"" 
mortality rate during a 6-month follovv-up [18J. 
In 1989, Rossie et al. published their results in 10 pa-
tients who underwent TIPS. They obtained a signif-
icant reduction in the portal pressure ", .. ithout re-
bleeding episodes during a 3-9 months follow-up [45]. 
In 1990, Roberts et al. performed a TIPS procedure 
by using a percutaneous transjugular and percuta-
neous transhepatic approach in a liver transplan t 
candidate with acute variceal bleeding. The creation 
of the intrahepatic portosystemic shunt was fol-
lowed bv an immediate cessation of variceal bleed-
ing. In spite of a recurrent hemorrhage, the patient 
underwent successful OLTx [46]. 
Richter et a!. reported on 24 cirrhotic patients in 
which a surgical shunt was not indicated and who 
therefore underwent TIPS. A successful TIPS was 
obtained in 75'1<, of cases \A,'ith a 43'X, drop in the 
mean portal pressure. The 30-days mortality rate 
was 11 '/'o and in only 1 patient was death related to a 
technical problem during the TIPS procedure. Dur-
ing a 2-year follow-up these authors reported a 50"/" 
total mortality rate [43]. 
Zemel et a1. performed TIPS in H patients and ob-
tained a drop in the average portal pressure from 36 
to 11 mmHg. In 5 cases an 8 mm stent was used, in 2 
cases a 10 mm stent and in 1 case a 12 mm stent. Up-
per endoscopy was performed two weeks after TIPS 
in all patients and showed universal variceal de-
compression. One patient rebleed from rectal vari-
ces. This patient was treated by increasing the shunt 
size from 8 to 12 mm. There was no other episode of 
rebleeding or patient death during a follow-up rang-
ing from 1 to 9 months [31]. 
Recently, larger series of TIPS have been reported, 
as proof that this technique of portal decompression 
is gaining increasing acceptance. 
Althaus et al. reported on 62 patients who under-
went TIPS. Indications included active bleeding 
from esophagogastric varices and intractable ascites. 
Only 14% of patients experienced rebleeding epi-
sodes due to thrombosis of the shunt. The most sig-
nificant complications were hepatic encephalopathy 
(13%) and hepatic trauma (7%) [47]. 
Barton et al. have published a series of 60 patients 
with recurrent variceal bleeding treated with TIPS. 
The mean PY pressure drop was from 38.5 to 23.8 
mmHg. The rebleeding rate was 20%. The mortality 
rate during a mean follow-up period of 6.5 months 
was 21.6%. In this study, they compared the Cian-
turco-Rosch Z stent with the Wallstent and did not 
find any significant difference between the two 
stents [48]. 
Zemel et a!. reported on 55 TIPS patients with a 
follow-up of 2-24 months (mean 7.6 months). The 
percentage of thrombosis or stenosis of the shunt, 
including HY stenosis, was 11 %,. The mortality rate 
was 11 % and mild encephalopathy, easily controlled 
with medical therapy, was observed in 9% of cases. 
Ascites disappeared in 95% of patients [49]. 
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LaBerge et al. reported on 100 TIPS patients. Nine-
tY-four of these were done for active variceal bleed-
ing. 3 for recurrent ascites, 2 for hepato-renal syn-
drome and 1 for preoperative portal decompression 
before OLTx. The technical success rate was 96%. 
After TIPS they observed a 35'Yc, drop in the portal 
pressure. Shunt stenosis or obstruction occurred in 
1RKSE~yIK During a 6-month follow-up the incidence of 
rebleeding episodes and mortality was lOA 'Yo and 
2T;o, respectively [36]. 
Savin et al. reported their experience in 42 TIPS 
patients; 22 were classified as Child Band 16 as 
Child C. The indication for TIPS was active variceal 
bleeding in 96% of cases and recurrent ascites resis-
tant to medical therapy. After TIPS they observed a 
drop in the mean portosystemic pressure gradient 
from 17 to 7 mmHg. Recurrent hemorrhage was ob-
served in 14% of the cases and the incidence of en-
cephalopathy was 13% r38]. 
Richter et al. reported their results on 120 patients 
who underwent TIPS during a 5-year period. The 
mean portosystemic pressure gradient reduction 
was from 29 to 12 mmHg. The stenosis rate was 
12.3'X" mainly localized at the level of the HY. The 
survival rate' at 30 days, 1 year, and 3 vears was 
94.7%, 68%, and 42'!o: respe'ctively [50]. ' 
Zajko et al. from our Institution reported their ex-
perience using TIPS in 45 patients (Child class: A = 
10, B = 26, C = 9). Indications included variceal 
bleeding in 44 and intractable ascites in 1. Palmaz 
stents were used in the first 21 patients and WalI-
stents in the last 24. Routine follow-up portal venog-
raphy was performed at 3, 6 and 12 months post 
TIPS. Successful TIPS was obtained in 100% of cases 
with a drop in the average portosystemic gradient 
from 27 to 11 mmHg. Thirty-day mortality was 6.7%. 
With a mean follow-up of 8 months, variceal bleed-
ing occurred in 6.7%; 13 patients underwent OLTx. 
The most significant problem reported by these au-
thors was stenosis of the HV occurring in 36% of 
cases. Stenosis of the shunt due to pseudointimal 
hyperplasia within the stent occurred in 7%. Most 
cases of HV stenosis occurred in shunts created with 
the Palmaz stent. Most of these patients were 
asymptomatic with the stenoses detected during 
routine shunt follow-up portal venography or Dop-
pler ultrasound. HV stenosis was treated with shunt 
Tab. 3.1. Worldwide experience. 
Thrombosisl Encephalopathy Authors stenoses (%) (%) 
Althaus [47] 14 13 
Barton [48] 15 -
laBerge [36] 15.60 17.70 
Maynar [54] 19.50 -
Richter [SO] 12.30 -
Savin [38] 14 13 
Saxon [52] 66 -
Zajko [57] 36 -
Zemel [49] 11 9.10 
F. Bartoli. A. Zajko. I.R. Marino et ai. 
revision using the Wallstent, balloon angioplasty, or 
both r51]. 
COMPLICATIONS 
Because of limited reported experience, it is diffi-
cult to determine the exact incidence of complica-
tions related to the TIPS procedure. The different 
techniques used and personal experience play an 
important role in determining the nature and in-
cidence of complications observed. 
The most frequent complications after TIPS are 
thrombosis or stenosis of the shunt or HV (Fig. 3.2 
A), the development of hepatic encephalopathy and 
recurrent hemorrhage (Table. 3.1). 
The incidence of shunt thrombosis or stenosis in-
cluding HV stenosis ranges from 10 to 66% [35, 36, 
38,47-49,51, 54, 55] and is the main cause of rebleed-
ing episodes. However, most cases of shunt stenoses 
are detected on routine follow-up portal venography 
during the first 6 months (unpublished data). Pseu-
dointimal hyperplasia is the main factor causing 
shunt obstruction r32, 51-53, 55]. Doppler ultrasound 
may be useful in determining shunt patency. It has 
been reported that a blood flow velocity through the 
shunt >60 cmlsec or <50 cm/sec is an index of shunt 
patency or outflow stenosis, respectively [56]. 
Thromboses or stenoses of the shunt are generally 
treated by balloon dilatation and/or by placement of 
additional stents (Fig. 3.2 B) [31, 36,41, 48, 49, 51, 54, 
57]. In other cases it mav be necessary to establish a 
new intrahepatic shunt '[36, 49, 53, 58]. 
As with all portosystemic shunts, TIPS can also 
cause hepatic encephalopathy [36, 38, 47,49]. Some 
investigators reported a 13% incidence of encepha-
lopathyafter TIPS. This result is similar to that re-
ported after porto systemic shunt performed with a 
small size graft of 8-10 mm in diameter [59, 60]. In 
general, this kind of encephalopathy responds well 
to the medical therapy permitting a good quality of 
life [57, 59-61]. 
Regardless of the kind of stent used (Palmaz, Wall-
stent, etc.), migration of the stent into the pulmonary 
artery or right atrium has been reported [31, 57, 62]. 
Bleeding Mortality Follow-up 
recurrence (%) (months) N. of patients (%) 
14 0 - 62 
20 21.60 1-26 60 
10.40 27 2-24 100 
19.50 12 1-12 41 
- 58 0-60 120 
14 0 - 42 
19 - 2-24 21 
6.70 6.70 1-.12 45 
5.5 11 2-24 . 55 
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Fig. 3.2. Shunt malfunction caused by outflow stenosis of the hepatic vein treated by shunt revision with a Walistent. 
A. Severe stenosis of the hepatic vein (arrows) at the level of venous outflow from the shunt. In this patient. the initial shunt was 
created with a Palmaz stent. The outflow stenosis has resulted in recurrence of gastroesophageal varices and marked increase 
in intrahepatic portal vein flow. The portosystemic gradient was 20 mmHg. 
B. Following shunt revision. portography shows complete decompression of varices. a marked reduction in intrahepatic flow. and 
excellent flow through shunt into the inferior vena cava. Shunt revision was performed through the previous Palmaz stent and 
across the hepatic vein stenosis. The hepatic venous outflow is now widely patent and the portosystemic gradient was reduced 
to 6 mmHg. 
This complication can be treated by removing the 
stent with an angiographic catheter (in the case of a 
Wallstent) [31, 62J. A Palmaz stent may have to be 
moved and expanded in the pulmonary artery or the 
IVC. Although there are no studies that demonstrate 
the superiority of one stent over another, some in-
vestigators believe that the Wallstent is less frequent-
ly involved in migration phenomenon because of its 
higher elasticity [62]. 
Less common complications of TIPS include in-
traperitoneal hemorrhage [35, 63), hemobilia [35, 53], 
puncture of the gallbladder or colon [35], acute renal 
failure [53, 64J, thrombosis of PV or jugular vein [61], 
sepsis [57, 63J, acute respiratory distress [61], hepatic 
trauma and myocardial ischemia [38, 47]. 
DISCUSSION 
TIPS induces hemodynamic changes very similar 
to those obtained after a surgical portosystemic shunt 
using synthetic grafts of different diameter (8-12 
mm). Clinical results are also similar, particularly 
when comparing the incidence of shunt obstruction, 
the percentage of rebleeding episodes and the fre-
quency of portosystemic encephalopathy [59, 60, 65, 
66]. However, TIPS has several advantages over a sur-
gical portosystemic shunt. With TIPS the patient does 
not undergo the stress and the risk of an operation 
and it may be possible to modify the size of the shunt 
according to the individual hemodynamiC character-
istics [21, 22,43,67]. Because of its moderate invilsive 
nature, TIPS is main Iv indicated in those Child's C pa-
tients at increased risk for surgery [43), where the 
mortality rute ilfter surgical portosystemic shunt has 
been reported to range from 40 to 100% [27]. 
The main technical progress responsible for TIPS 
larger clinical use are the introduction of balloon ex-
pandable (Pillmaz) [19, 20, 68J and self-expanding 
(Wallstent) [32, 69] metallic vascular stents, more rig-
id needles (that allow a better angle of puncture and 
easier perforation of the hepatic tissue) and the use 
of high definition Doppler ultrasound for PV local-
ization [44, 56, 70]. 
The Palmaz stent and Wallstent are the most wide-
ly used stents . Advantages of the Palmaz stent in-
clude flexibility in the size and, therefore, the ability 
to regulate the hemodynamic effect of the shunt as 
documented by pressure gradients; in addition a rel-
atively precise positioning is possible. Disadvantag-
es of this stent include the larger-size sheath neces-
sary for introduction and its lack of longitudinal flex-
ibility, which sometimes makes insertion more diffi -
cult than with other types of devices [57). Also be-
cause of its rigidity, a relatively central puncture of 
the main right or left PV is necessary. Advantages of 
the Wallstent include the use of a somewhat smaller 
delivery system and the ability to puncture any PV 
branch because of the inherent f1exibilitv of the 
stent. Disadvantages include less precise pO'sitioning 
due to the significant shortening of the stent after 
deployments and limitation in the fixed outer diame-
ter of 10 mm, which may theoretically necessitate 
additional shunts in some patients [57J . 
B 
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After the intrahepatic portosvstemic shunt i" 
made, the pressure gradient between the PV and the 
HV is measured to determine the efficacy of the 
shunt. Investigators have observed that rebleeding 
episodes are unlikely if the portosystemic gradient is 
<12 mmHg [71, 72]. However, others have reported 
that the percentage decrease in the portosystemic 
gradient is a more important predictive factor than 
the absolute final gradient [73]. 
If portal decompression is not adequate following 
TIPS, it may be possible to increase the shunt size (in 
the case of a Palmaz stent shunt) until a diameter of 
10-12 mm or perform transcatheter variceal embo-
lization [21,31, 32, 43]. If TIPS has been created with 
a Wallstent, variceal embolization or an additional 
shunt may be performed [55, 58]. 
Recently, it has been reported that 77% of patients 
with an intrahepatic shunt of 8 mm in diameter re-
quired variceal embolization; however, this proce-
dure was performed in only 36% of patients with an 
intrahepatic shunt of 10 mm in diameter [33]. 
It has been suggested that TIPS, as with other por-
tosvstemic shunts, can result in deterioration of liver 
fmiction, mainly in those patients undergoing an 
emergent TIPS or those with Child's C liver disease 
[74]. Recently, however, no deterioration of liver 
function after TIPS has been reported during a 6-
month follow-up [75]. The incidence of hepatic en-
cephalopathy has been reported to range from 0 to 
35'10 [36-38,40,47,49, 57, 75]. This wide range of re-
sults can be due to different groups of patients in-
cluded in the studies, to the size of the intrahepatic 
shunt, and to different follow-up periods. 
In studies citing disproportionately low incidence 
of hepatic encephalopathy, the question of inade-
quate follow-up must be raised. The disappearance 
of intractable ascites has been observed in 70-100';1" 
of the patients undergoing TIPS [31, 37, 40, 48, 49, 55, 
57]. Therefore, an increased number of patients have 
undergone TIPS where the main indication was as-
cites resistant to medical therapy, periodic paracen-
tesis, and peritoneal venous shunts [36, 37, 39, 40, 
47,53]. 
The incidence of rebleeding episodes following 
TIPS has been reported to range from 11 to 20% on 
long-term follow-up (20-26 months) [35, 48]. For sur-
gical portosystemic shunts, as for TIPS, rebleeding 
episodes are mainly secondary to shunt obstruction 
or to HV outflow problems [35, 36, 38,47-49, 51, 54]. 
Recently, Richter et al. [50] and LaBerge et al. [36] 
F. Bartoli. A. Zajko. I.R. Manno et ai, 
reported a short-term (30 days) mortalitv rate of 
RKPD~;I and 1PE~EFI respectively. For the long-term (3 
years 50; 20 months 36) mortal it\' was of 58';" and 
27%, respecti\·elv. Most of those 'patients were clas-
sified as Child B or C, patients in whom emergent 
surgical porta-caval shunt was not indicated becausl' 
of the extremely high operative risk. 
An increasing number of liver transplant pro-
grams are using TIPS as the technique of choice for 
portal decompression. Portal hypertensive patients 
undergoing a porta-caval shunt have an increased 
operative risk, mainl~D related to the presence of ad-
hesions and stenosis or thrombosis of the PY. Such 
complications significantly enhance the technical 
difficulty during OLTx [12, 13]. In patients with 
TIPS, the stent can be easilv removed with the liver 
during OLTx. . 
For these reasons, in the last vears, at our In-
stitution we have performed only a limited number 
of surgical portosystemic shunts despite the high 
number of OLTx performed [12, 13]. 
CONCLUSIONS 
TIPS is an exciting new interventional radiologic 
technique for the treatment of PH, which should on-
ly be performed in an angiographic suite where high 
resolution fluoroscopy and digital angiography are 
available, as well as experts trained in interventiona I 
radiological techniques. In addition, TIPS should be 
performed in hospitals where an experienced surgi-
cal team in hepatobiliar\' surgery is available. 
Despite its new clinical introduction, TIPS is a safe 
and effective technique of portal decompression, 
mainly useful in that group of patients with acute 
variceal bleeding or in patients with recurrent bleed-
ing unresponsive to sclerotherapy. 
Therefore, TIPS can replace the emergent surgical 
portosystemic shunt. 
With increased clinical experience, it may replace 
the elective surgical portosystemic shunt in well se-
lected cases. 
TIPS plays an important role in the management 
of portal hypertensive related bleeding in OLTx can-
didates, permitting a "bridge effect" in avoiding fur-
ther bleeding episodes while a suitable donor be-
comes available. 
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